Cargando…

The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective

BACKGROUND AND AIM: The optimal sarcopenia measurement method in patients with a diagnosis of glioblastoma multiforme (GBM) is unknown. It has been found that temporal muscle thickness (TMT) may reflect sarcopenia and be associated with survival, but the relationship between temporal muscle area (TM...

Descripción completa

Detalles Bibliográficos
Autores principales: SÜTCÜOĞLU, Osman, ERDAL, Zeynep Sezgi, AKDOĞAN, Orhun, ÇELTİKÇİ, Emrah, ÖZDEMİR, Nuriye, ÖZET, Ahmet, UÇAR, Murat, YAZICI, Ozan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific and Technological Research Council of Turkey (TUBITAK) 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388072/
https://www.ncbi.nlm.nih.gov/pubmed/36945944
http://dx.doi.org/10.55730/1300-0144.5599
_version_ 1785082029026574336
author SÜTCÜOĞLU, Osman
ERDAL, Zeynep Sezgi
AKDOĞAN, Orhun
ÇELTİKÇİ, Emrah
ÖZDEMİR, Nuriye
ÖZET, Ahmet
UÇAR, Murat
YAZICI, Ozan
author_facet SÜTCÜOĞLU, Osman
ERDAL, Zeynep Sezgi
AKDOĞAN, Orhun
ÇELTİKÇİ, Emrah
ÖZDEMİR, Nuriye
ÖZET, Ahmet
UÇAR, Murat
YAZICI, Ozan
author_sort SÜTCÜOĞLU, Osman
collection PubMed
description BACKGROUND AND AIM: The optimal sarcopenia measurement method in patients with a diagnosis of glioblastoma multiforme (GBM) is unknown. It has been found that temporal muscle thickness (TMT) may reflect sarcopenia and be associated with survival, but the relationship between temporal muscle area (TMA) and GBM prognosis has never been evaluated before. The primary outcome of the study was to evaluate the relationship between TMA/TMT and overall survival (OS) time in newly diagnosed GBM patients. MATERIALS AND METHODS: The data of patients who presented at the university hospital between January 2009 and January 2019 with a confirmed diagnosis of glioblastoma multiforme at the time of diagnosis were analyzed retrospectively. Temporal muscle thickness and TMA were measured retrospectively from preoperative MRIs of patients diagnosed with GBM. Due to the small number of patients and the failure to determine a cut-off value with acceptable sensitivity and specificity using ROC analysis, the median values were chosen as the cut-off value. The patients were basically divided into two according to their median TMT (6.6 mm) or TMA (452 mm(2)) values, and survival analysis was performed with the Kaplan–Meier analysis. RESULTS: The median TMT value was 6.6 mm, and the median TMA value was 452 mm(2). The median overall survival (OS) was calculated as 25.8 months in patients with TMT < 6.6 mm, and 15.8 months in patients with TMT ≥ 6.6 mm (p = 0.29). The median overall survival (OS) of patients with TMA < 452mm(2) was 26.3 months, and the group with TMA ≥ 452mm(2) was 14.6 months (p = 0.06). The median disease-free survival was 18.3 months (%95 CI: 13.2–23.4) in patients with TMT < 6.6mm, while mDFS was 10.9 (%95 CI: 8.0–13.8) months in patients with TMT ≥ 6.6mm (p = 0.21). The median disease-free survival was found to be 21.0 months (%95 CI: 15.8–26.1) in patients with TMA < 452 mm(2) and 10.5 months (%95 CI: 7.8–13.2) in patients with TMA ≥ 452 mm(2) (p = 0.018). CONCLUSION: No association could be demonstrated between TMT or TMA and OS of GBM patients. In addition, the median DFS was found to be longer in patients with low TMA. There is an unmet need to determine the optimal method of sarcopenia in GBM patients.
format Online
Article
Text
id pubmed-10388072
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Scientific and Technological Research Council of Turkey (TUBITAK)
record_format MEDLINE/PubMed
spelling pubmed-103880722023-08-01 The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective SÜTCÜOĞLU, Osman ERDAL, Zeynep Sezgi AKDOĞAN, Orhun ÇELTİKÇİ, Emrah ÖZDEMİR, Nuriye ÖZET, Ahmet UÇAR, Murat YAZICI, Ozan Turk J Med Sci Research Article BACKGROUND AND AIM: The optimal sarcopenia measurement method in patients with a diagnosis of glioblastoma multiforme (GBM) is unknown. It has been found that temporal muscle thickness (TMT) may reflect sarcopenia and be associated with survival, but the relationship between temporal muscle area (TMA) and GBM prognosis has never been evaluated before. The primary outcome of the study was to evaluate the relationship between TMA/TMT and overall survival (OS) time in newly diagnosed GBM patients. MATERIALS AND METHODS: The data of patients who presented at the university hospital between January 2009 and January 2019 with a confirmed diagnosis of glioblastoma multiforme at the time of diagnosis were analyzed retrospectively. Temporal muscle thickness and TMA were measured retrospectively from preoperative MRIs of patients diagnosed with GBM. Due to the small number of patients and the failure to determine a cut-off value with acceptable sensitivity and specificity using ROC analysis, the median values were chosen as the cut-off value. The patients were basically divided into two according to their median TMT (6.6 mm) or TMA (452 mm(2)) values, and survival analysis was performed with the Kaplan–Meier analysis. RESULTS: The median TMT value was 6.6 mm, and the median TMA value was 452 mm(2). The median overall survival (OS) was calculated as 25.8 months in patients with TMT < 6.6 mm, and 15.8 months in patients with TMT ≥ 6.6 mm (p = 0.29). The median overall survival (OS) of patients with TMA < 452mm(2) was 26.3 months, and the group with TMA ≥ 452mm(2) was 14.6 months (p = 0.06). The median disease-free survival was 18.3 months (%95 CI: 13.2–23.4) in patients with TMT < 6.6mm, while mDFS was 10.9 (%95 CI: 8.0–13.8) months in patients with TMT ≥ 6.6mm (p = 0.21). The median disease-free survival was found to be 21.0 months (%95 CI: 15.8–26.1) in patients with TMA < 452 mm(2) and 10.5 months (%95 CI: 7.8–13.2) in patients with TMA ≥ 452 mm(2) (p = 0.018). CONCLUSION: No association could be demonstrated between TMT or TMA and OS of GBM patients. In addition, the median DFS was found to be longer in patients with low TMA. There is an unmet need to determine the optimal method of sarcopenia in GBM patients. Scientific and Technological Research Council of Turkey (TUBITAK) 2022-11-20 /pmc/articles/PMC10388072/ /pubmed/36945944 http://dx.doi.org/10.55730/1300-0144.5599 Text en © TÜBİTAK https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Research Article
SÜTCÜOĞLU, Osman
ERDAL, Zeynep Sezgi
AKDOĞAN, Orhun
ÇELTİKÇİ, Emrah
ÖZDEMİR, Nuriye
ÖZET, Ahmet
UÇAR, Murat
YAZICI, Ozan
The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective
title The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective
title_full The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective
title_fullStr The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective
title_full_unstemmed The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective
title_short The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective
title_sort possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388072/
https://www.ncbi.nlm.nih.gov/pubmed/36945944
http://dx.doi.org/10.55730/1300-0144.5599
work_keys_str_mv AT sutcuogluosman thepossiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT erdalzeynepsezgi thepossiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT akdoganorhun thepossiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT celtikciemrah thepossiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT ozdemirnuriye thepossiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT ozetahmet thepossiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT ucarmurat thepossiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT yaziciozan thepossiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT sutcuogluosman possiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT erdalzeynepsezgi possiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT akdoganorhun possiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT celtikciemrah possiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT ozdemirnuriye possiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT ozetahmet possiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT ucarmurat possiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective
AT yaziciozan possiblerelationbetweentemporalmusclemassandglioblastomamultiformeprognosisviasarcopeniaperspective